Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Inizio

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog...

Inizio

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global...

Inizio

- PMLiVE

Find your match in digital pharma marketing

Our Digital Lead, Richard Springham, looks at how to apply matchmaking lessons from Tinder to your own digital marketing.

Four Agency Worldwide

- PMLiVE

Chiesi Group’s Trimbow wins European licence

European Commission approves the COPD treatment

- PMLiVE

Two new starters boost Wave’s senior team

Sadaf Kazi and Dr Florentia Loizou join the group

- PMLiVE

Medmeme bolsters sales team

Appoints Jeff Sager as senior vice president

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

- PMLiVE

Xtandi slowdown weighs on Pfizer, but CEO won’t move on M&A

Investors call on the pharma giant to consider a large merger or acquisition deal

AstraZeneca AZ

Clock starts ticking on FDA review of AZ’s acalabrutinib

If approved, the BTK inhibitor could achieve annual peak sales of $5bn

- PMLiVE

Truthful consumerism

Amid all the change and uncertainty of this moment,  a set of core truths about our shared future is as relevant as ever

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links